Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Brief Summary: This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.


Options:
A: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
B: Arm Label: AIN457 150mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: etanercept | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo, Etanercept, Placebo | Intervention Type: DRUG; Name: secukinumab (AIN457); Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept
C: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo

Answer: B